PMID- 25912212
OWN - NLM
STAT- MEDLINE
DCOM- 20160217
LR  - 20181113
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Linking)
VI  - 34
IP  - 6
DP  - 2015 Jun
TI  - Changes of serum levels of MMP-3, sRANKL, and OPG in juvenile-onset ankylosing 
      spondylitis patients carrying different HLA-B27 subtypes.
PG  - 1085-9
LID - 10.1007/s10067-015-2940-z [doi]
AB  - Ankylosing spondylitis (AS) patients whose symptom onset occurs before 16 years 
      of age are termed juvenile-onset ankylosing spondylitis (JAS). Investigations 
      suggested that JAS had worse functional outcome, and abnormality of bone 
      metabolism can appear in early stage of AS. The objectives of this study are to 
      compare changes of serum inflammatory and bone metabolic markers and to explore 
      the relationship between these biomarkers and disease activity in JAS with 
      different HLA-B27 subtypes. Serum matrix metallopeptidase-3 (MMP-3), soluble 
      receptor activator of nuclear factor-kappaB ligand (sRANKL), and osteoprotegerin 
      (OPG) were detected by ELISA in 56, 62, and 68 JAS patients, respectively, and 32 
      healthy individuals were as controls. Serum MMP-3 and sRANKL were significantly 
      higher and OPG in JAS was slightly higher than those in controls. There was no 
      significant difference in the level of MMP-3, sRANKL, and OPG among JAS patients 
      with B27 negativity, B*2704, B*2705, and B*2715, respectively. Serum levels of 
      MMP-3 showed positive correlation with BASDAI and BASFI (Bath Ankylosing 
      Spondylitis Disease Activity Index and Functional Index). Serum level of sRANKL 
      showed positive correlation with MMP-3 and negative correlation with disease 
      duration. The significantly higher sRANKL expression suggested the enhanced 
      osteoclast function and imbalance of RANKL/OPG system in the inflammatory process 
      of JAS patients carrying different B27 subtypes. It should be paid attention to 
      the abnormality of bone metabolism during the treatment of JAS.
FAU - Mou, Yi-Kun
AU  - Mou YK
AD  - Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, Guangdong, China.
FAU - Zhang, Ping-Ping
AU  - Zhang PP
FAU - Li, Qiu-Xia
AU  - Li QX
FAU - Lin, Zhi-Ming
AU  - Lin ZM
FAU - Liao, Ze-Tao
AU  - Liao ZT
FAU - Wei, Qiu-Jing
AU  - Wei QJ
FAU - Gu, Jie-Ruo
AU  - Gu JR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150426
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
RN  - 0 (Biomarkers)
RN  - 0 (HLA-B27 Antigen)
RN  - 0 (Osteoprotegerin)
RN  - 0 (RANK Ligand)
RN  - 0 (TNFRSF11B protein, human)
RN  - 0 (TNFSF11 protein, human)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age of Onset
MH  - Biomarkers/blood
MH  - Child
MH  - Female
MH  - HLA-B27 Antigen/genetics
MH  - Humans
MH  - Male
MH  - Matrix Metalloproteinase 3/*blood
MH  - Osteoprotegerin/*blood
MH  - RANK Ligand/*blood
MH  - Severity of Illness Index
MH  - Spondylitis, Ankylosing/*blood/epidemiology/genetics
MH  - Young Adult
EDAT- 2015/04/29 06:00
MHDA- 2016/02/18 06:00
CRDT- 2015/04/28 06:00
PHST- 2014/11/06 00:00 [received]
PHST- 2015/04/11 00:00 [accepted]
PHST- 2015/02/15 00:00 [revised]
PHST- 2015/04/28 06:00 [entrez]
PHST- 2015/04/29 06:00 [pubmed]
PHST- 2016/02/18 06:00 [medline]
AID - 10.1007/s10067-015-2940-z [doi]
PST - ppublish
SO  - Clin Rheumatol. 2015 Jun;34(6):1085-9. doi: 10.1007/s10067-015-2940-z. Epub 2015 
      Apr 26.